Theralase Technologies Inc.

Theralase Technologies Inc.

0.13
USD
+0.00
(-0.86%)
-0.01EPS
54.34MMarket Cap
Dec 02Next Earn

Total Valuation

USD

As of June 30, 2026, Theralase Technologies Inc. carries a market capitalization of 54.34M, placing it among publicly traded companies globally. Its enterprise value stands at 50.74M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap54.34M
Enterprise Value50.74M

Important Dates

Theralase Technologies Inc.'s next confirmed earnings release is scheduled for December 2, 2026.

Earnings Date12/2/2026

Share Statistics

As of June 30, 2026, Theralase Technologies Inc. has 295.67M shares outstanding.

Shares Outstanding295.67M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 86.54, and the price-to-book ratio stands at 11.27.

PS Ratio86.54
PB Ratio11.27
P/TBV Ratio11.27
P/FCF Ratio-20.62
P/OCF Ratio-20.49

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 89.74 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 50.74M versus a market cap of 54.34M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales89.74

Financial Position

As of June 30, 2026, Theralase Technologies Inc. maintains a current ratio of 5.48, meaning it holds 5.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.17, indicating elevated leverage, while an interest coverage ratio of -59.16 demonstrates limited ability to service its debt obligations.

Current Ratio5.48
Quick Ratio4.89
Debt / Equity2.17
Debt / EBITDA-0.04
Interest Coverage-59.16

Financial Efficiency

USD

Over the twelve months ended June 30, 2026, Theralase Technologies Inc. posted a negative return on equity (ROE) of -93.40, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -68.06, reflecting losses generated across the asset base. The company generates approximately 35,339.29 in revenue per employee across its workforce of 16.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.56 indicates how many times Theralase Technologies Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-93.40
Return on Assets (ROA)-68.06
Revenue Per Employee35,339.29
Employee Count16.00
Inventory Turnover0.56

Stock Price Statistics

USD

As of the close on November 16, 2026, Theralase Technologies Inc.'s stock has declined approximately 12.59% over the past 52 weeks. The 50-day moving average sits at 0.13, while the 200-day moving average is 0.18.

52-Week Price Change-12.59%
50-Day Moving Average0.13
200-Day Moving Average0.18

Income Statement

USD

Over the twelve months ended June 30, 2026, Theralase Technologies Inc. generated 565,428.65 in revenue and converted that into -2.67M in net income, yielding earnings per share of -0.01. EBITDA reached -2.51M, while operating income came in at -2.68M.

Revenue565,428.65
Gross Profit370,002.33
Operating Income-2.68M
Pretax Income-2.67M
Net Income-2.67M
EBITDA-2.51M
EBIT-2.68M
Earnings Per Share (EPS)-0.01

Balance Sheet

USD

As of June 30, 2026, Theralase Technologies Inc. holds 3.71M in cash and equivalents against 104,788.58 in total debt, resulting in a net debt position of -3.71M. Total book value stands at 4.82M, with working capital of 3.94M providing operational flexibility.

Cash & Cash Equivalents3.71M
Total Debt104,788.58
Net Debt-3.71M
Equity (Book Value)4.82M
Book Value Per Share0.02
Working Capital3.94M

Cash Flow

USD

Theralase Technologies Inc. produced -2.39M in operating cash flow over the twelve months ended June 30, 2026. After subtracting 15,110.52 in capital expenditures, free cash flow totaled -2.37M - equivalent to -0.01 per share.

Operating Cash Flow-2.39M
Capital Expenditures15,110.52
Free Cash Flow-2.37M
FCF Per Share-0.01

Margins

Over the twelve months ended June 30, 2026, Theralase Technologies Inc. posted a gross margin of 65.44, reflecting its pricing power and cost economics. The operating margin of -474.33 and net profit margin of -472.48 provide insight into operational efficiency.

Gross Margin65.44
Operating Margin-474.33
Pretax Margin-472.48
Profit Margin-472.48
EBITDA Margin-443.29

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -4.85: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -11.12, meaning Theralase Technologies Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-11.12
FCF Yield-4.85

Scores

As of June 30, 2026, Theralase Technologies Inc. has an Altman Z-Score of 22.72, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score22.72